Summary
Boston Scientific Corporation (BSX) announced a significant update regarding its Board of Directors' compensation. Effective for the remainder of the 2020 term, the annual cash retainer for non-employee directors will be restored to two-thirds of the originally approved amount. This restoration follows an earlier temporary reduction to one-half of the approved amount, implemented in April 2020 due to COVID-19 related uncertainties. The decision to restore compensation is driven by the company's stronger-than-expected business performance. This positive business trend indicates a potential rebound and improved financial outlook for Boston Scientific, which is a key signal for investors assessing the company's operational resilience and future prospects. The change will be reflected in payments made during the fourth quarter of 2020.
Key Highlights
- 1Board of Directors' cash retainer restored to two-thirds of the original amount.
- 2Restoration is effective for the remainder of the 2020 term.
- 3The previous reduction to one-half of the retainer was a temporary measure due to COVID-19 uncertainty.
- 4The restoration is attributed to stronger business results than initially anticipated.
- 5A payment related to the restored retainer is expected in the fourth quarter of 2020.
- 6Directors opting for equity in lieu of cash will receive an additional grant valued at one-sixth of the annual cash retainer.